Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Kura Oncology, Inc.NASDAQ: KURA
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 96.6%
Gross margin was 96.6% in Q1 FY2026, down 3.4 pp from a year earlier. On a trailing-twelve-month basis it was 94.7%, down 5.0 pp year over year.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 99.9%
- Year-over-year change
- -0.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 99.9% | -0.1pp |
| FY2024 | 2024-12-31 | 100.0% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Gross Margin vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 gross margin of 94.7% is the 2nd highest of the 7 companies compared; the peer median is 85.1%.
- Its year-over-year change of -5.0 pp is the 4th highest of 7, against a peer median of -8.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 98.0% | -0.0 pp | — | |
| LTM Mar 2026 | 94.7% | -5.0 pp | — | |
| LTM Mar 2026 | 93.4% | +3.7 pp | -5.2 pp | |
| LTM Aug 2026 | 86.5% | +249.4 pp | +455.2 pp | |
| LTM Mar 2026 | 83.7% | -16.3 pp | -17.1 pp | |
| LTM Jun 2025 | 8.9% | -20.9 pp | +11.6 pp | |
| LTM Mar 2026 | -2105.7% | -548.4 pp | +0.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | FY2025 | — | — | — |
| Peer median (excluding KURA) | 85.1% | -8.1 pp | +0.0 pp | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 53.88M | 67.48M |
| Cost of Revenue | 0 | 0 | 849K | 0 | 57K |
| Gross Profit | 0 | 0 | (849K) | 53.88M | 67.43M |
| Gross Margin | — | — | — | 100.0% | 99.9% |
| Research & Development | 84.72M | 92.81M | 115.24M | 169.97M | 251.07M |
| Selling, General & Admin | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| Operating Expenses | 131.26M | 139.87M | 164.96M | 247.08M | 371.06M |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | 1.03M |
| EBITDA | (129.49M) | (134.85M) | (150.23M) | (169.5M) | (275.83M) |
| EBITDA Margin | — | — | — | -314.6% | -408.7% |
| Operating Income | (131.26M) | (139.87M) | (165.8M) | (193.2M) | (303.63M) |
| Operating Margin | — | — | — | -358.5% | -449.9% |
| Interest Income | 1.21M | 4.25M | 14.72M | 22.85M | 26.77M |
| Interest Expense | 414K | 229K | 1.55M | 1.62M | 1.51M |
| Other Income / Expenses | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Income Before Tax | (130.47M) | (135.84M) | (152.63M) | (171.97M) | (278.37M) |
| Pre-Tax Margin | — | — | — | -319.1% | -412.5% |
| Income Tax Expense | 0 | 0 | 0 | 2.02M | 297K |
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Net Margin | — | — | — | -322.9% | -412.9% |
| EPS (Basic) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| EPS (Diluted) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| Weighted Avg Shares | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
| Weighted Avg Shares (Diluted) | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.